Mirum Pharmaceuticals, Inc.MIRMNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +89.37% | +42.93% | +61.20% | +64.09% | +47.17% |
| Gross Profit Growth | +85.54% | +72.08% | +72.34% | +81.04% | +54.48% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +16.26% | +3.46% | +4.18% | +5.28% | +21.59% |
| Weighted Average Shares Diluted Growth | +16.26% | +3.46% | +4.18% | +5.28% | +19.28% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | -112.89% | +0.00% | +896.01% |
| Free Cash Flow Growth | +0.00% | +0.00% | -113.17% | +0.00% | +0.00% |
| Receivables Growth | +43.27% | +15.18% | +74.28% | +76.79% | +56.33% |
| Inventory Growth | -2.95% | +0.41% | +3.76% | +12.25% | +11.24% |
| Asset Growth | +2.65% | +3.73% | +5.87% | +9.85% | +17.55% |
| Book Value per Share Growth | -25.83% | -12.29% | -4.56% | +5.85% | +3.52% |
| Debt Growth | +3.14% | +3.12% | +3.13% | +0.74% | +0.35% |
| R&D Expense Growth | +21.42% | +42.32% | +42.90% | +41.00% | +35.48% |
| SG&A Expenses Growth | +38.37% | +23.05% | +26.44% | +28.61% | +22.48% |